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Abstract
Background: Research predicting the public health and fiscal impact of Supervised Injection Facilities (SIFs), across different 
cities in Canada, has reported positive results on the reduction of HIV cases among People Who Inject Drugs (PWID). 
Most of the existing studies have focused on the outcomes of Insite, located in the Vancouver Downtown Eastside (DTES). 
Previous attention has not been afforded to other affected areas of Canada. The current study seeks to address this deficiency 
by assessing the cost-effectiveness of opening a SIF in Saskatoon, Saskatchewan.
Methods: We used two different mathematical models commonly used in the literature, including sensitivity analyses, to 
estimate the number of HIV infections averted due to the establishment of a SIF in the city of Saskatoon, Saskatchewan.
Results: Based on cumulative cost-effectiveness results, SIF establishment is cost-effective. The benefit to cost ratio was 
conservatively estimated to be 1.35 for the first two potential facilities. The study relied on 34% and 14% needle sharing rates 
for sensitivity analyses. The result for both sensitivity analyses and the base line estimates indicated positive prospects for the 
establishment of a SIF in Saskatoon.
Conclusion: The opening of a SIF in Saskatoon, Saskatchewan is financially prudent in the reduction of tax payers’ expenses 
and averting HIV infection rates among PWID. 
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Implications for policy makers
• Supervised Injection Facilities (SIFs) can be cost-effective even in small urban cities.
• SIFs are highly efficient entities that are able to reduce morbidity cases among People Who Inject Drugs (PWID).
• SIFs are also able to reduce overdose and other injection related illnesses. 
Implications for public
North America’s first and only Supervised Injection Facility (SIF) (Insite), has shown to be cost-effective with substantial savings to the local healthcare 
system relative to averting HIV, hepatitis C and overdose cases among People Who Inject Drugs (PWID). Moreover, numerous peer-reviewed research have 
demonstrated SIFs’ cost-savings in the context of large and medium sized Canadian cities. It is important that despite the controversial nature of SIFs, they 
have shown to be highly cost-effective in reducing HIV even in small cities with high rates of PWID. 
Key Messages 
Background
The contraction and spread of HIV via People Who Inject 
Drugs (PWID) is not a problem exclusive to large cities 
and urban areas as small and medium sized towns have 
reported an increase in HIV infection (1). The Downtown 
Eastside (DTES) of Vancouver has historical shared 
similarities with many small cities in Canada in terms of 
HIV prevalence. Vancouver DTES has long been recognized 
for its composition of impoverished and dispossessed drug 
users and is currently home to more than 5,000 PWID (2). 
In the late 1990s, the DTES experienced one of the highest 
HIV and Hepatitis C Virus (HCV) infection in the developed 
world that was comparable to the epidemic in third world 
nations, such as Botswana (3,4). Since early 2000, the DTES 
has been positively transformed as a result of long standing 
harm reduction programs that have addressed an array of 
PWID needs, particularly the establishment of Insite, North 
America’s only lawfully operated Supervised Injection Facility 
(SIF) (5–10).
Insite, located in the DTES of Vancouver, is a small injection 
facility with twelve individual booths that afford PWID with 
free sterile injection supplies to inject illicit drugs under the 
supervision of a registered nurse (11) (Figure 1). 
Insite also offers its clientele access to social workers, doctors 
and a detoxification center located in close proximity to the 
facility (12). The procedural objectives of Insite have been 
assessed by more than 60 peer-reviewed studies offering 
promising results. Some of the noted effects are reduction 
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in overdose deaths, needle sharing, public injection and 
public discarded needles (12–14). In addition, most 
empirical analysis have reported cost-effectiveness of Insite 
in reducing HIV, HCV and overdose cases (4,15–18). More 
recently, a longitudinal study has suggested that the rate of 
needle sharing decreased substantially overtime along with a 
secondary effect in the reduction of HIV contractions (11). 
Consequently, there has been discussions among health 
experts and policy-makers as to the expansion of Insite in 
Vancouver and the implementation of the facility in other 
affected areas of Canada. One of the most pressing issues 
regarding the institution or expansion of Insite facilities is the 
effectiveness and cost-efficiency of SIF. This issue is of critical 
importance as the Canadian conservative federal government 
recently passed legislation Bill C-65 (now called Bill C2): the 
Respect for Communities Act, requiring that SIF operations be 
found economically viable within affected regions (11). 
Further studies have assessed the cost-effectiveness of opening 
a SIF in Montreal, Ottawa and other drug affected regions in 
Canada. A recent study conducted in Montreal estimated the 
number of HIV and HCV cases averted with the opening of a 
potential SIF in the city (19). Expected fiscal savings amounted 
to more than three million Canadian dollars in HIV and HCV 
prevention (19). In a similar study conducted in Ottawa, the 
effects of opening a SIF in the city were examined (10). The 
Figure 1. Insite, North America’s first and only SIF (photo provided 
by authors).
sensitivity analyses at separate baseline sharing demonstrate 
the cost-effectiveness of SIF at a 19% needle sharing; at this 
baseline the cumulative annual cost model provided support 
for the establishment of two SIF and the marginal annual cost 
model for one SIF (10).
A recent cost-benefit ratio study suggests that supervised 
inhalation rooms, where drug users could smoke crack and 
crystal methamphetamine under supervision, has a saving 
potential of Can$1.45 per year for each facility (20). The cost-
benefit/cost-effectiveness analysis focused on HCV cases and 
the rate of transmission via a contaminated crack pipe. The 
results infer that the expansion of the facility would be of great 
utility to other affected regions in Canada (20). The current 
study focuses on the densely affected city of Saskatoon, 
Saskatchewan. Scant attention has been paid to the possibility 
of a SIF in the city and the benefits that such establishment 
may accrue. Saskatoon has an estimated population of 2,000 
PWIDs, concentrated in the poorest neighborhoods in the 
city, most of whom are affected by poverty, low educational 
attainment and have meager access to job opportunities (21). 
Morphine and powdered cocaine are the two most preferred 
drugs of choice among PWIDs. And, most users utilizes an 
average of 1,000 needles per year (21). 
Since 1993, the government of Saskatoon has made attempts 
to reduce the incidence of HIV through needle exchange 
outreach programs and has increased funding toward related 
programs. Nonetheless, most of these endeavors have been 
unsuccessful in curtailing needle sharing practices among 
PWIDs. As a result, the incidence of HIV cases has sharply 
increased and is felt most acutely within the Indigenous 
population of Saskatoon where 9.2% of the Indigenous 
population accounts for 88.1% of PWID and 77.4% of the 
PWID Indigenous population has tested positive for HIV (3). 
The increase incidence of HIV among the Indigenous PWID 
population has been attributed to a history of colonization, 
residential school programs and lack of available non-
judgmental services tailored specifically toward this 
group (3). In addition, many of Indigenous population of 
Saskatoon reside in area of the city that has “higher rates of 
unemployment, lower education levels, a higher proportion of 
residents living below the low income cut-off (47% in 2006), 
higher rates of inadequate housing and limited access to 
nutritious and affordable food” (22) (p. 10). Subsequently, it is 
not surprising that these areas have also shown higher rates of 
health disparities (23,24).
The authors elected Saskatoon as the study site due to its 
high HIV prevalence. With miniscule attention previously 
afforded to Saskatoon’s PWID population, the authors hope 
to simulate the economic possibilities of SIF in reducing 
morbidity related diseases in this region. The study utilizes 
a cost-benefit and cost-effectiveness analysis employing HIV 
data and sharing needle cases in Saskatoon to determine the 
prospects of a SIF within the city. The analysis project the new 
HIV cases prevented as a result of establishing SIF and the 
possible benefits and costs of scaling up additional facilities. 
Subsequently, the avoided monetary costs of HIV cases are 
compared to the operating costs of potential facilities. Due to 
the unavailability of key parameters, HCV cases were excluded 
from the analysis, which made the costing study more 
conservative in reporting the benefits of SIF in Saskatoon.
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Methods
Models
The current study focuses on two different mathematical 
models to estimate the number of HIV prevented as a result of 
establishing a SIF in Saskatoon. The first model was initially 
used in Edmonton, Alberta’s evaluation of a needle exchange 
program in 1999. Later, the model was used in an economic 
evaluation of Insite (14–18,25,26). In addition, the model 
has been used to estimate the cost-benefit/cost-effectiveness 
of a SIF potential in Montreal, Quebec, and Ottawa, Ontario 
(10,19). The model has been employed to assess the economic 
viability of a supervised smoking facility in the DTES of 
Vancouver (20). 
For the current model, the number of new HIV infections 
averted, (A), is calculated as follows: 
New HIV infections (A) = 1Nsd[1– (1 – qt)m]                         (1)
where (d) is the percentage of needles not cleaned before 
use, (N) is the number of needles in circulation, (q) is the 
HIV prevalence in the PWID population, (I) is the PWID 
population that is HIV positive, (s) is the rates of needle 
sharing, (t) is the probability of HIV transmission when using 
an HIV infected needles, and (m) is the number of sharing 
partners when injections are shared. 
This study also relied on a second model to estimate the 
number of HIV prevented. The second model was originally 
used in the evaluation of New Haven, Connecticut needle 
depot in 1993 (27). The model was later utilized in the 
economic evaluation of North America’s first supervised 
injection facility and in predicating the cost-effectiveness of 
a potential SIF in Ottawa, Ontario. The number of new HIV 
infections avoided, (A), is calculated as follows:
New HIV infection (A) = (1 – π) λ(1 – θ)βα
where (β) is the percent of HIV infected needles, (λ) is the 
rate of needle sharing, (π) is the prevalence of HIV within 
the PWID population, (α) is the probability of acquiring HIV 
from a single injection with contaminated syringe, and (θ) is 
the probability that a borrowed syringe is decontaminated 
(27). The data for both mathematical models were collected 
from published and peer-reviewed articles (see Table 1). To 
reduce selection bias, the values and parameters that were the 
most conservative in their reporting were selected (10,17,19, 
20,26). In addition, preferences were given to peer-reviewed 
studies when other sources were available. 
Marginal or cumulative benefits and costs are a critical part 
of any economical evaluation as they provide the relevant 
measurement of cost/benefits at a specific level of production 
and consumption (28,29). In simpler terms, marginal benefit 
and cost are the measurement of benefits or cost of producing 
one more unit. However, the cumulative benefits and cost 
accounts for the total measurement. 
Infectious disease cases prevented 
Previous costing studies have illustrated that SIF prevent 
shared or ‘dirty’ injections (10,15–19,28,29). Behavioral 
changes for those who attend SIF has been highlighted as an 
important factor in previous literature as well (30,31). Similar 
to previous costing studies, the current study employs Odds 
Ratio (OR) of 0.3 for behavioral change (10,17,19,20). Since we 
cannot expect all PWID to start utilizing SIF and eventually 
alter their injecting behavior, OR of 0.3 was only employed 
twice (for the first and second SIF only) (10,17,19,20). 
Ultimately, we limit the number of new users to Saskatoon’s 
SIF by using the 0.3 OR. The total number of illicit drug 
injections per year in the city of Saskatoon was calculated 
by multiplying the number of PWID by number of injection 
per year estimated in a number of peer-reviewed studies 
[e.g. 2,000 PWID × 913 injections per year] (6,25,28,32,33). 
This number called G [estimated to be 1,826,000 injections 
per year] was later multiplied by the initial sharing rate to 
determine the number of shared injections in the city of 
Saskatoon. 
The total number of injections at a SIF in Saskatoon was 
estimated to be 315,360 injections per year [V] [e.g. 3 
injection per hour × 24 hours × 365 days × 12 booths]. V was 
estimated based on the reported injection that takes place 
on daily basis at Insite (34). For instance, 600 [T] injections 
take place at Insite in Vancouver (34). Subsequently, a ratio 
of 3 injection per 60 minutes is derived when T is divided by 
216 [18 hours of operation at Insite × 12 booths operating]. 
Averted shared injections [Z] is derived when V is multiplied 
by the sharing rate [0.24]. After considering the OR [0.30], 
G is added to Z to determine the total potential prevented 
cases of needle sharing in the city of Saskatoon. The rate with 
a SIF, and the rate without a SIF is subsequently estimated 
and the difference is calculated. This method is repeated with 
increased numbers of SIFs.
The medical cost of new HIV 
A 1996 New York data estimated the cost-effectiveness of 
needle exchange between $90,000 to $200,000 from HIV 
Table 1. Sources for variables used in the first and second models
Variable Value Source
Proportion of IDUs HIV- (I) 85.00% Laurence Thompson Strategic Consulting (21)
Rate of needle sharing (s) or (λ) 24.00% Laurie and Green (36)
Number of needles in circulation (N) 1,000,000 Warren (37)
Percentage of needles not cleaned (d) 17.00% Kaplan and O’Keefe (27); Jacobs et al. (25)
Probability of HIV infections from a single injection (t) or (α) 0.67% Kaplan and O'Keefe (27)
Number of sharing partners (m) 1.38 Jacobs et al. (25)
Proportion of IDUs HIV+ (q) or (π) 15.00% Laurence Thompson Strategic Consulting (21)
Proportion of HIV infected needles (β) 40.50% Kaplan and O'Keefe (27)
Probability of needles cleaned (θ) 83.00% Kaplan and O'Keefe (27); Jacobs et al. (25)
IDUs= Injection Drug Users.
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cases averted (33,35). A similar costing study in Hamilton, 
Ontario estimated the life time treatment of HIV at $150,000 
(38). In Edmonton, a costing study of needle exchange 
estimated the lifetime cost of treating HIV to be $94,000 
(39). A comprehensive review of needle exchange program 
in Saskatchewan estimated the cost of treating a person with 
HIV to be $120,000 (21). In the United States, the lifetime 
cost of HIV care is approximately $395,000 (38) while the 
Canadian cost is slightly lower at Can$210,555. The value 
of Can$210, 555 or $169,100 is chosen for its conservative 
estimate, assuming a lower cost-savings for HIV infections 
among PWID [to convert the Canadian to American dollar 
simply multiply by 0.81]. This lower cost assumption is based 
on the most recent literature that recognizes certain self-
imposed barriers that make treatment less likely within the 
PWID population (4,10,19,26).
Cost of Supervised Injection Facility (SIF) 
The only available comparison facility in North America is 
Insite in Vancouver. As a result we draw upon the most recent 
data from Insite’s operational cost which is estimated to be 
Can$3 million (10,18,19,26,39). The Can$3 million or $2.40 
million figure includes additional services, such as addiction 
counseling, primary healthcare, public health screening, 
immunization, diagnostic peer counseling, case management, 
education, and housing services (10,18,19,26,39). The 
estimated cost will be lower (Can$1.53 million or $1.23 
million) if the annual operating cost of Insite only considers 
ancillary equipment, staff salaries, property rental, and 
equipment purchases (37). An Insite expansion from 18 to 24 
hours adds an additional Can$0.652 million or $0.525 million 
to the annual operating cost of Insite where the operational 
cost of Insite reaches Can$2.182 million or $1.757 million 
(10,18,19,26). For simplicity, we assume that the Saskatoon 
SIF would provide comparable costs associated with staff 
salaries, equipment purchases, and property rental as the SIF 
in Vancouver. 
Results
The number of HIV prevented was predicted based on needle 
sharing. Table 2 and 3 demonstrated that increasing the 
scope of SIF in Saskatoon also increases the number of HIV 
prevented. Based on Table 2, cost-saving does not disappear 
for SIF in Saskatoon when the cumulative data is taken into 
consideration. In fact, the cost-saving ranges from $1,529,940 
for the second SIF to a low value of $533,220 for the fourth 
potential SIF. Based on cumulative cost-effectiveness results, 
SIF establishment is cost-effective up to four facilities in 
Saskatoon. For example, the cumulative cost-effectiveness 
ranges from $198,436 to $145,520. The cumulative benefit-
cost ratio is also above unity for the first four facilities. For 
instance, the cumulative benefit-cost ratios for HIV range 
from 1.44 to 1.06.
According to Table 3, the marginal cost savings are more 
modest. In fact, after the second facility, cost savings 
diminishes. Similarly, the marginal cost-effectiveness shown 
in Table 3 indicates that after the second facility, the expansion 
will not be cost-effective. For example, the marginal cost-
effectiveness ratios for HIV range from $145,520 to $272,850. 
Based on Table 3, the marginal benefit-cost ratio for HIV 
is above unity for the first two facilities. For instance, the 
marginal benefit-cost ratios according to Table 3 range from 
1.44 to 0.77 for HIV cases.
Moreover, the cost-savings diminishes after the second 
facility. For example, the cost-saving of $975,525 diminishes 
to a loss of $498,360. Sensitivity analyses conducted at 
different baseline sharing rates also demonstrated that 
establishing SIF based on HIV averted may save tax payers’ 
dollars (see Table 2 and 3). The current analysis used 14% and 
34% initial needle-sharing for the sensitivity analysis. The 
second model also demonstrated that establishing more than 
one SIF in Saskatoon may save tax payers money. As shown 
in Table 4, the cumulative cost-effectiveness ratios range 
from $155,914 to $207,886 and the cumulative benefit to cost 
ratios are again above unity for the first four potential SIF. 
Based on Table 4, the marginal values of the second model 
are also similar to the cumulative values, thereby supporting 
the establishment of SIF in Saskatoon. To illustrate, the cost-
effectiveness ratios range from $155,914 to $272,850 and 
benefit-cost ratios are above unity for the first two potential 
SIF. On average, benefit-to-cost ratios are never below unity 
for the first two facilities with an average of 1.32.
Discussion
Based on the first two models and subsequent sensitivity 
analysis, establishing at least two SIF in Saskatoon is cost-
effective. The SIF is warranted as there is still a high incidence 
of HIV among Saskatoon PWID despite success of current 
Table 2. The cumulative annual cost-effectiveness and cost-benefit of SIF in Saskatoon using the first model
Variables Annual cost of operation Sharing rate
Number of HIV 
averted HIV Cost saved
Cost-effectiveness ratio 
HIV Cost-benefit ratio HIV
First SIF $2,182,800 17% 15 $975,525 $145,520 1.44
(24%, 10%) (21, 9) ($2,238,855, -$287,805) ($103,943, $242,533) (2.03, 0.87)
Two SIFs $4,365,600 10% 28 $1,529,940 $155,914 1.35
(14%, 6%) (39, 16) ($3,846,045, -$996,720) ($272,850, $272,850) (1.90, 0.77)
Three SIFs $6,548,400 6% 36 $1,031,580 $181,900 1.16
(9%, 4%) (51, 21) ($4,189,905, -$2,126,745) ($128,400, $311,829) (1.60, 0.68)
Four SIFs $8,731,200 2% 44 $533,220 $198,436 1.06
(3%, 1%) (63, 26) (4,533,765, -$3,256,770) ($138,590, $335,815) (1.50, 0.63)
SIF= Supervised Injection Facility.
Note: The numbers in parentheses represent the results of the sensitivity analysis: (34% sharing, 14% sharing). Numbers in bold represent the loss. 
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needle exchange programs (21). In Saskatoon, HIV reports 
were more than three times that of the national average 
(40,41). The annual incidence report for Saskatoon was 31.3 
per 100,000 persons in comparison to the national average of 
9.3 per 100,000 persons (2,21). Additionally, the majority of 
Saskatoon’s HIV reports were attributed to PWID (76.9%), 
while the nation’s average of PWID contribution to HIV was 
18.9% (2). 
Current drug policy strategies in Saskatoon are inept at 
reducing the co-morbidity cases among the disadvantaged 
Indigenous group. A recent study conducted in Saskatoon 
demonstrated that PWID encounter multiple barriers when 
attempting to access harm reduction services which include 
but not limited to system deficiencies, poor communication, 
discrimination by healthcare providers and police and 
insufficient financial resources (42–44). Consequently, the 
health authority needs to take a paradigm shift toward more 
effective harm reduction programs in addition to the services 
that are being already provided. We suggest that harm 
reduction services in Saskatoon should include SIF as part of 
healthcare delivery to this vulnerable population. 
The results of the current study suggest that establishment of 
at least two SIF in Saskatoon will on average prevent at least 14 
new HIV cases. This translates into cost savings of $764,970 
for the first two facilities. Moreover, the establishment of SIF 
in Saskatchewan’s largest city appears to be cost-effective. 
In fact, cost-effective and cost-benefit ratios suggest that 
the establishment of at least two SIF in Saskatoon will 
increase taxpayer’s revenue. It is important to emphasize that 
Vancouver once paralleled Saskatoon morbidity cases during 
the late 1990s (45). But, peer-driven harm reduction programs 
were able to successfully decrease morbidity and mortality 
cases in the DTES (9). The primary difference between both 
cities is the higher concentration and greater size of the PWID 
population in Saskatoon, which fosters a greater need for the 
implementation of harm reduction programs as evinced in 
Vancouver.
Recent qualitative studies conducted in Saskatoon suggests 
that the city could benefit from experimenting with smaller 
scale harm reduction approaches that rely on peer drug 
users to disseminate information and skills to the most 
marginalized PWID (42,43). Accordingly, the study suggests 
that this type of “program is ideal for smaller urban centers 
where social networks may be closer than in a larger city …. 
Additionally, such a program would take advantage of the fact 
that IDUs in Saskatoon receive a large proportion of drug use 
safety information from their peers” (42) (p. 9). 
SIF that have been operating in Vancouver have been 
effective in reducing HIV, lethal overdoses, needle sharing 
and publicly discarded syringes. These facilities have been 
successful in improving service uptake, improved public 
order, and increasing the probability of initiating and 
maintaining addiction treatment (9,12–14,34,46–51). SIFs 
have the potential to “reduce viral and bacterial infections 
and overdose mortality among those who engage in high-risk 
injection behaviors by offering unique public health services 
that are complementary to other interventions” (52) (p. 100). 
Additionally, SIF in Vancouver has been a key venue for 
obtaining care for infections and encouraging safer injection 
methods (12,48). 
Theoretical possibilities of SIF expansion needs to be decided 
on by the local health authorities on the basis of scientific 
evidence supporting such expansion (17). Public awareness 
by the local health policy-makers and doctors regarding SIF 
Table 3. The marginal annual cost-effectiveness and cost-benefit of SIF in Saskatoon using the first model
Variables Annual cost of operation Sharing rate
Number of HIV 
averted HIV Cost-saved Cost-effectiveness ratio HIV
Cost-benefit ratio 
HIV
First SIF $2,182,800 17% 15 $975,525 $145,520 1.44
(24%, 10%) (21, 9) ($2,238,855, -$287,805) ($103,943, $242,533) (2.03, 0.87)
Two SIFs $2,182,800 10% 13 $554,415 $167,908 1.25
(14%, 6%) (18, 8) ($1,607,190, -$498,360) ($121,267, $272,850) (1.74, 0.77)
Three SIFs $2,182,800 6% 8 -$498,360 $272,850 0.77
(9%, 4%) (12, 5) ($343,860, -$1,130,025) ($181,900, $436,560) (1.16, 0.48)
Four SIFs $2,182,800 2% 8 -$498,360 $272,850 0.77
(3%, 1%) (12, 5) ($343,860, -$1,130,025) ($181,900, $436,560) (1.16, 0.48)
SIF= Supervised Injection Facility.
Note: The numbers in parentheses represent the results of the sensitivity analysis: (34% sharing, 14% sharing). Numbers in bold represent the loss. 
Table 4. The cumulative and marginal cost-effectiveness and cost-benefit of SIF in Saskatoon using the second model
Variables Annual cost of operation Sharing rate #of HIV averted Cost-effectiveness ratio HIV Cost-benefit ratio HIV
First SIF $2,182,800 17% 14 $155,914 1.40
($2,182,800) (17%) (14) ($155,914) (1.40)
Two SIFs $4,365,600 10% 26 $167,908 1.30
($2,182,800) (10%) (12) ($181,900) (1.20)
Three SIFs $6,548,400 6% 34 $192,600 1.10
($2,182,800) (6%) (8) ($272,850) (0.77)
Four SIFs $8,731,200 2% 42 $207,886 1.01
($2,182,800) (2%) (8) ($272,850) (0.77)
SIF= Supervised Injection Facility. 
Note: The numbers in parentheses represent the marginal results.
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will allow the community to be better educated about the 
benefits of these harm reduction programs and the role they 
play in reducing crime, drug dealing, public injection, and a 
host of other social maladies (9,12–14,34,46–51). Community 
support is a fundamental part of sustaining the program 
and it will ultimately help in conceptualizing injection drug 
use as a health issue, rather than a moral one (11,16,53). 
There are numerous example of activism by peer drug user 
organization in Canada. Vancouver Area Network of Drug 
Users (VANDU) and the Sandy Hill community center in 
Ottawa, are some examples of where drug users have been 
able to successfully advocate for their rights and a SIF in their 
respected cities (8,10,54). 
The current study has several limitations. The first limitation 
pertains to the exclusive focus on HIV cases. Other costing 
studies, that have considered Insite and its potential role for 
expansion in other cities, have included HCV in the cost-
benefit analysis (10,18–20). However, the current study 
due to unavailability of key parameters had to rely on HIV 
cases alone which made the costing study more conservative 
in reporting the benefits of SIF in Saskatoon. However, the 
most noteworthy limitation of this study concerns the static 
mathematical models used in the analysis. Such models omit 
Quality-Adjusted Life Years (QALYs). In fact, our models may 
be considered simple in comparison to other more complex 
models that consider the dynamics of the social system and a 
score of parameters, such as secondary sexual transmission, 
effects of attending methadone therapy and increase in the 
population of drug users. 
Conclusion
Through the use of two mathematical models this study has 
shown that SIF in Saskatoon are indeed cost-saving. The 
models in this paper are similar to that used by five other 
costing studies that also show economic viability of SIF and 
other harm reduction programs (10,17,19,20,26). This paper 
shows that the associated cost-savings related to the number 
of new HIV infections averted is large enough to cover the 
cost of operating more than one SIF in Saskatoon. It is our 
hope that the results of the study will encourage community 
activists and government officials to make a paradigm shift 
toward harm reduction programs that will aid and protect at 
risk PWID population.
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